Angiotensin II in the Perioperative Management of Hypotension in Kidney Transplant Recipients

PHASE4CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

August 13, 2020

Primary Completion Date

August 1, 2021

Study Completion Date

August 1, 2021

Conditions
Shock, SurgicalShockHypotension and ShockKidney Transplant; ComplicationsIntraoperative HypotensionPostoperative Hypotension
Interventions
DRUG

Angiotensin II

If intraoperative or postoperative hypotension occurs (e.g. SBP \< 120 mmHg) and the attending surgeon and/or attending anesthesiologist deems vasopressor therapy to be necessary, angiotensin II (Giapreza) will be the first vasopressor used for management.

Trial Locations (1)

60612

University of Illinois Hospital and Health Sciences System, Chicago

Sponsors
All Listed Sponsors
collaborator

La Jolla Pharmaceutical Company

INDUSTRY

lead

University of Illinois at Chicago

OTHER

NCT04529005 - Angiotensin II in the Perioperative Management of Hypotension in Kidney Transplant Recipients | Biotech Hunter | Biotech Hunter